Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): ##STR00001##
wherein
ring A is a heterocycle, X.sup.1 is each independently CR.sup.4aR.sup.4b, X.sup.2 is each independently CR.sup.4cR.sup.4d, Y.sup.1 and Y.sup.2 are each independently a carbon atom or a nitrogen atom,
L is —N(R.sup.6)—C(═O)— or the like, W is cyclyl or the like, R.sup.2 and R.sup.3 are each independently substituted or unsubstituted alkyl or the like, R.sup.1a, R.sup.1b, R.sup.4a to R.sup.4d, and R.sup.6 are each independently hydrogen atoms or the like,
p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.

Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): ##STR00001##
wherein
ring A is a heterocycle, X.sup.1 is each independently CR.sup.4aR.sup.4b, X.sup.2 is each independently CR.sup.4cR.sup.4d, Y.sup.1 and Y.sup.2 are each independently a carbon atom or a nitrogen atom,
L is —N(R.sup.6)—C(═O)— or the like, W is cyclyl or the like, R.sup.2 and R.sup.3 are each independently substituted or unsubstituted alkyl or the like, R.sup.1a, R.sup.1b, R.sup.4a to R.sup.4d, and R.sup.6 are each independently hydrogen atoms or the like,
p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.

Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,

##STR00001##

and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,

##STR00001##

and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

The present invention discloses a nitrogen-containing heterocyclic substituted benzoxazine oxazolidinone compound, a preparation method and use thereof in the manufacture of a medicament for treating and/or preventing infectious diseases caused by Mycobacterium tuberculosis. Specifically, the present invention relates to a compound represented by formula (I) and stereoisomer thereof, pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compounds of the present invention, use thereof, a method for preparing the compound, in which X.sub.1, X.sub.2, R.sub.1 and R.sub.2 are described in the specification.

The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.

Macrocyclic Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, and Formula VIII or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Macrocyclic Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, and Formula VIII or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.

The present invention provides a novel macrocyclic prodrug compound of general Formula (I), a pharmaceutical composition comprising a compound of Formula (I), and a method for treating diseases mediated by HDAC enzymes by administering a compound of Formula (I), wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, A and Z are defined herein.

##STR00001##